Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Kiniksa Pharmaceuticals International (NASDAQ:KNSA)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $48.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 19.79% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Finally, Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.00.

Kiniksa Pharmaceuticals International Stock Down 2.1%

Shares of NASDAQ:KNSA traded down $0.86 during midday trading on Tuesday, hitting $40.07. The stock had a trading volume of 235,507 shares, compared to its average volume of 609,214. The company’s 50-day moving average price is $39.19 and its 200-day moving average price is $33.63. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $42.98. The company has a market capitalization of $3.04 billion, a P/E ratio of 89.05 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same period last year, the business earned ($0.18) earnings per share. The business’s revenue was up 61.2% compared to the same quarter last year. Research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,470 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $41.24, for a total value of $514,262.80. Following the completion of the transaction, the chief operating officer directly owned 22,714 shares in the company, valued at approximately $936,725.36. This represents a 35.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the transaction, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at $4,340,961.02. The trade was a 46.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 622,713 shares of company stock worth $23,616,219. Company insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth approximately $31,000. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at approximately $32,000. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $33,000. Finally, Quantbot Technologies LP bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $43,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.